Drug Information
| Drug General Information | |||||
|---|---|---|---|---|---|
| Drug ID |
D02NNN
|
||||
| Former ID |
DNCL002079
|
||||
| Drug Name |
CBP-501
|
||||
| Drug Type |
Small molecular drug
|
||||
| Indication | Mesothelioma [ICD9: 163; ICD10:C45] | Phase 1/2 | [522352] | ||
| Company |
CanBas
|
||||
| Structure |
|
Download2D MOL |
|||
| Formula |
C86H122F5N29O17
|
||||
| Canonical SMILES |
C1CCC(CC1)CC(C(=O)NC(CCCNC(=N)N)C(=O)NC(CCCNC(=N)N)C(=O<br />)NC(CCCNC(=N)N)C(=O)NC(CCC(=O)N)C(=O)NC(CCCNC(=N)N)C(=O<br />)NC(CCCNC(=N)N)C(=O)O)NC(=O)C(CC2=C(C(=C(C(=C2F)F)F)F)F<br />)NC(=O)C(CO)NC(=O)C(CC3=CNC4=CC=CC=C43)NC(=O)C(CO)NC(=O<br />)C(CC5=CC=C(C=C5)C(=O)C6=CC=CC=C6)N
|
||||
| InChI |
1S/C86H122F5N29O17/c87-64-49(65(88)67(90)68(91)66(64)89)39-60(118-80(135)62(42-122)120-77(132)59(38-47-40-109-51-19-8-7-18-48(47)51)117-79(134)61(41-121)119-70(125)50(92)36-44-25-27-46(28-26-44)69(124)45-16-5-2-6-17-45)78(133)116-58(37-43-14-3-1-4-15-43)76(131)113-54(22-11-33-106-84(98)99)72(127)110-52(20-9-31-104-82(94)95)71(126)111-53(21-10-32-105-83(96)97)73(128)114-56(29-30-63(93)123)75(130)112-55(23-12-34-107-85(100)101)74(129)115-57(81(136)137)24-13-35-108-86(102)103/h2,5-8,16-19,25-28,40,43,50,52-62,109,121-122H,1,3-4,9-15,20-24,29-39,41-42,92H2,(H2,93,123)(H,110,127)(H,111,126)(H,112,130)(H,113,131)(H,114,128)(H,115,129)(H,116,133)(H,117,134)(H,118,135)(H,119,125)(H,120,132)(H,136,137)(H4,94,95,104)(H4,96,97,105)(H4,98,99,106)(H4,100,101,107)(H4,102,103,108)/t50-,52-,53-,54-,55-,56-,57-,58-,59-,60-,61-,62-/m1/s1
|
||||
| InChIKey |
DEZJGRPRBZSAKI-KMGSDFBDSA-N
|
||||
| PubChem Compound ID | |||||
| PubChem Substance ID | |||||
| Target and Pathway | |||||
| Target(s) | MARK3 | Target Info | Inhibitor | [550418] | |
| MAPKAP kinase 2 | Target Info | Inhibitor | [550418] | ||
| NetPath Pathway | IL2 Signaling Pathway | ||||
| WikiPathways | Serotonin Receptor 4/6/7 and NR3C Signaling | ||||
| Serotonin Receptor 2 and ELK-SRF/GATA4 signaling | |||||
| Serotonin HTR1 Group and FOS Pathway | |||||
| p38 MAPK Signaling Pathway | |||||
| MAPK Signaling Pathway | |||||
| FAS pathway and Stress induction of HSP regulation | |||||
| MAP kinase activation in TLR cascade | |||||
| Regulation of mRNA Stability by Proteins that Bind AU-rich Elements | |||||
| Arachidonic acid metabolism | |||||
| Structural Pathway of Interleukin 1 (IL-1) | |||||
| Regulation of Microtubule Cytoskeleton | |||||
| IL-1 signaling pathway | |||||
| NGF signalling via TRKA from the plasma membrane | |||||
| MAPK targets/ Nuclear events mediated by MAP kinases | |||||
| References | |||||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.